Clinical Trials 2011: Year in Review
Clinical Trials 2011: Year in Review
A phase 2A study comparing intranasal oxytocin with placebo in 80 patients suffering from treatment-refractory chronic daily headache was initiated by Trigemina, Inc. and MedVadis Research Corporation in late 2009. In May 2010, an interim analysis was reported for 25 subjects. The data showed that 47% of oxytocin-treated patients vs 11% of placebo patients reported at least a 50% reduction in pain scores. The complete study results were expected in 2011 but have yet to be reported.
Chronic Daily Headache
Oxytocin Intranasal (TI-001, Syntocinon)
A phase 2A study comparing intranasal oxytocin with placebo in 80 patients suffering from treatment-refractory chronic daily headache was initiated by Trigemina, Inc. and MedVadis Research Corporation in late 2009. In May 2010, an interim analysis was reported for 25 subjects. The data showed that 47% of oxytocin-treated patients vs 11% of placebo patients reported at least a 50% reduction in pain scores. The complete study results were expected in 2011 but have yet to be reported.
